Bimagrumab

Generic Name: Bimagrumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1356922-05-8

Unique Ingredient Identifier: N15SW1DIV8

Background: Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Phase 2

Recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Tirzepatide
Drug: Bimagrumab
Drug: Placebo

First Posted Date: 2024-10-16

Last Posted Date: 2025-01-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 140

Registration Number: NCT06643728

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida, United States

and more 7 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy